Genetic Characteristics of Metastatic Breast Cancer Patients

Overview

Genomic analysis for metastatic breast cancer(MBC) patients – Participant (Inclusion criteria) 1. Patients who diagnosed metastatic/stage IV breast cancer 2. Patients who were not received treatment for metastatic breast cancer on palliative setting – Process (1) Tissue/ Blood sample – At diagnosis, MBC tissue / blood sample (20cc) will be obtained. – At disease progression after 1st line treatment for MBC, blood sample (20cc) will be obtained (tissue; optional) (2) WES, RNASeq, ctDNA, Exosome – We will analyze genomic characteritics using WES, RNASeq, ctDNA, Exosome.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Health Services Research
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 31, 2024

Interventions

  • Diagnostic Test: Genomic analysis
    • WES, RNASeq, ctDNA, Exosome

Arms, Groups and Cohorts

  • Other: Metastatic breast cancer cohort
    • Metastatic breast cancer with genetic tests including WES, RNASeq, ctDNA and exosome

Clinical Trial Outcome Measures

Primary Measures

  • Genomic profiling of MBC patients
    • Time Frame: 60 months
    • Gemetic alteration frequency, the association between genetic alteration and survival

Participating in This Clinical Trial

Inclusion Criteria

  • Patients who diagnosed ad metastatic breast cancer – Patients who were not received treatment on palliative setting Exclusion Criteria:

  • Patients who did not agree this study – Patients who did not have any pathologic specimen at MBC diagnosis.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Samsung Medical Center
  • Provider of Information About this Clinical Study
    • Principal Investigator: Young-Hyuck Im, Professor – Samsung Medical Center
  • Overall Contact(s)
    • Young-Hyuck Im, MD,PhD, 82-2-3410-3459, yh00.im@samsung.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.